Stock data
Relay Therapeutics, Inc. (RLAY)
Relay Therapeutics, Inc. (RLAY) reported revenue of US$15.36M and net income of -US$276.48M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$15.36M | — | -US$302.74M | -US$276.48M | — |
| 2024 | US$10.01M | — | -US$372.47M | -US$337.71M | — |
| 2023 | US$25.55M | — | -US$373.00M | -US$341.97M | — |
| 2022 | US$1.38M | — | -US$299.27M | -US$290.51M | — |
| 2021 | US$3.03M | — | -US$364.70M | -US$363.87M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$0.35M | -US$83.71M | — |
| 2026-03-31 | US$3.00M | -US$73.29M | — |
| 2025-12-31 | US$7.00M | -US$54.89M | — |
| 2025-09-30 | US$0.00M | -US$74.15M | — |
| 2025-06-30 | US$0.68M | -US$70.38M | — |
| 2025-03-31 | US$7.68M | -US$77.06M | — |
| 2024-12-31 | US$0.00M | -US$76.00M | — |
| 2024-09-30 | US$0.00M | -US$88.11M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.